Literature DB >> 34515205

Neurokinin-1 Antagonism Distinguishes the Role of Norepinephrine Transporter from Dopamine Transporter in Mediating Amphetamine Behaviors.

Padmanabhan Mannangatti1, Durairaj Ragu Varman1, Sammanda Ramamoorthy1, Lankupalle D Jayanthi1.   

Abstract

BACKGROUND: Amphetamine (AMPH) and other psychostimulants act on the norepinephrine (NE) transporter (NET) and the dopamine (DA) transporter (DAT) and enhance NE and DA signaling. Both NET and DAT share anatomical and functional characteristics and are regulated similarly by psychostimulants and receptor-linked signaling pathways. We and others have demonstrated that NET and DAT are downregulated by AMPH and substance P/neurokinin-1 receptor (NK1R)-mediated protein kinase C pathway.
OBJECTIVES: Since both NET and DAT are downregulated by AMPH and NK1R activation and share high sequence homology, the objective of the study was to determine the catecholamine transporter specificity in NK1R modulation of AMPH-induced behaviors.
METHODS: The effect of NK1R antagonism on AMPH-induced conditioned place preference (CPP) as well as AMPH-induced NET and DAT downregulation was examined using NET and DAT knockout mice (NET-KO and DAT-KO) along with their wild-type littermates.
RESULTS: Aprepitant (5 mg/kg i.p.) significantly attenuated AMPH (2 mg/kg i.p.)-induced CPP in the wild-type and DAT-KO but not in the NET-KO. Locomotor activity measured during the post-conditioning test (in the absence of AMPH) showed higher locomotor activity in DAT-KO compared to wild-type or NET-KO. However, the locomotor activity of all 3 genotypes remained unchanged following aprepitant. Additionally, in the ventral striatum of wild-type, the AMPH-induced downregulation of NET function and surface expression but not that of DAT was attenuated by aprepitant.
CONCLUSIONS: The results from the current study demonstrate that aprepitant attenuates the expression of AMPH-induced CPP in DAT-KO mice but not in NET-KO mice suggesting a role for NK1R-mediated NET regulation in AMPH-induced behaviors.
© 2021 S. Karger AG, Basel.

Entities:  

Keywords:  Aprepitant; Conditioned place preference; Dopamine transporter knockout mice; Locomotor activity; Neurokinin-1 receptor; Norepinephrine transporter knockout mice

Mesh:

Substances:

Year:  2021        PMID: 34515205      PMCID: PMC8578286          DOI: 10.1159/000518033

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   3.429


  43 in total

1.  Rab11 supports amphetamine-stimulated norepinephrine transporter trafficking.

Authors:  Heinrich J G Matthies; Jessica L Moore; Christine Saunders; Dawn Signor Matthies; Lynne A Lapierre; James R Goldenring; Randy D Blakely; Aurelio Galli
Journal:  J Neurosci       Date:  2010-06-09       Impact factor: 6.167

2.  Differential effects of aprepitant, a clinically used neurokinin-1 receptor antagonist on the expression of conditioned psychostimulant versus opioid reward.

Authors:  Padmanabhan Mannangatti; Santhanalakshmi Sundaramurthy; Sammanda Ramamoorthy; Lankupalle D Jayanthi
Journal:  Psychopharmacology (Berl)       Date:  2016-12-24       Impact factor: 4.530

Review 3.  Monoamine transporter inhibitors and substrates as treatments for stimulant abuse.

Authors:  Leonard L Howell; S Stevens Negus
Journal:  Adv Pharmacol       Date:  2014

4.  Phosphorylation of the norepinephrine transporter at threonine 258 and serine 259 is linked to protein kinase C-mediated transporter internalization.

Authors:  Lankupalle D Jayanthi; Balasubramaniam Annamalai; Devadoss J Samuvel; Ulrik Gether; Sammanda Ramamoorthy
Journal:  J Biol Chem       Date:  2006-06-01       Impact factor: 5.157

Review 5.  Psychostimulants affect dopamine transmission through both dopamine transporter-dependent and independent mechanisms.

Authors:  Ike Dela Peña; Ruzanna Gevorkiana; Wei-Xing Shi
Journal:  Eur J Pharmacol       Date:  2015-07-21       Impact factor: 4.432

6.  Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression.

Authors:  Mark S Kramer; Andrew Winokur; Jeffrey Kelsey; Sheldon H Preskorn; Anthony J Rothschild; Duane Snavely; Kalyan Ghosh; William A Ball; Scott A Reines; Dennis Munjack; Jeffrey T Apter; Lynn Cunningham; Mitchel Kling; Mohammed Bari; Albert Getson; Yih Lee
Journal:  Neuropsychopharmacology       Date:  2004-02       Impact factor: 7.853

7.  Chronic cocaine self-administration upregulates the norepinephrine transporter and alters functional activity in the bed nucleus of the stria terminalis of the rhesus monkey.

Authors:  Darrel J Macey; Hilary R Smith; Michael A Nader; Linda J Porrino
Journal:  J Neurosci       Date:  2003-01-01       Impact factor: 6.167

8.  Extracellular dopamine, norepinephrine, and serotonin in the nucleus accumbens of freely moving rats during intracerebral dialysis with cocaine and other monoamine uptake blockers.

Authors:  M Y Li; Q S Yan; L L Coffey; M E Reith
Journal:  J Neurochem       Date:  1996-02       Impact factor: 5.372

9.  Interference of norepinephrine transporter trafficking motif attenuates amphetamine-induced locomotor hyperactivity and conditioned place preference.

Authors:  Padmanabhan Mannangatti; Sammanda Ramamoorthy; Lankupalle Damodara Jayanthi
Journal:  Neuropharmacology       Date:  2017-10-04       Impact factor: 5.250

10.  Glycogen synthase kinase-3ß supports serotonin transporter function and trafficking in a phosphorylation-dependent manner.

Authors:  Durairaj Ragu Varman; Lankupalle D Jayanthi; Sammanda Ramamoorthy
Journal:  J Neurochem       Date:  2020-09-07       Impact factor: 5.546

View more
  1 in total

1.  Blunted Amphetamine-induced Reinforcing Behaviors and Transporter Downregulation in Knock-in Mice Carrying Alanine Mutations at Threonine-258 and Serine-259 of Norepinephrine Transporter.

Authors:  Durairaj Ragu Varman; Padmanabhan Mannangatti; Mark A Subler; Jolene J Windle; Sammanda Ramamoorthy; Lankupalle D Jayanthi
Journal:  J Mol Neurosci       Date:  2022-07-19       Impact factor: 2.866

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.